GH1 and neoplasm: To define the therapeutic efficacy of SRL treatment, the effects on both GH/IGF-1 secretion and tumor mass are considered, these parameters being generally evaluated after 6–12 months of therapy with both octreotide LAR and lanreotide ATG at “conventional” maximal doses (i.e., 30 mg/28 days and 120 mg/28 days, respectively) [128, 129].